Ein vorrangiges Therapieziel bei Patienten mit Diabetes mellitus im hohen Lebensalter ist der Erhalt der Lebensqualität und die Vermeidung von therapiebedingten Akutkomplikationen. Sollten
Lebensstiländerungen nicht ausreichen, um das individuelle Therapieziel zu erreichen, besteht die Indikation zur medikamentösen Therapie. In diesem Beitrag werden die Besonderheiten der oralen
antidiabetischen Therapie bei älteren Menschen mit Typ-2-Diabetes erläutert.
Abstract
Sodium-glucose linked transporter 2 (SGLT-2) inhibitors and oral glucagon-like peptide-1 (GLP-1) analogues are among the new oral antidiabetic agents. primary therapeutic goal in the elderly
is to maintain quality of life and avoid treatment-related acute complications such as hypoglycemia. The individual abilities and resources as well as treatment wishes of older people must be
taken into account when determining therapy goals and the therapy of diabetes mellitus. SGLT-2 inhibitors can also be used in older people with diabetes. Their advantage is lowering blood
glucose without an inherent hypoglycemic risk, as well as reduced cardiovascular morbidity and mortality and a nephroprotective effect in people with type 2 diabetes and preexisting
cardiovascular disease. During use, increased risks for mycotic genital infections, polyuria, and desiccosis should be noted. In rare cases, normoglycemic ketoacidosis may occur. The article
discusses the specifics of oral antidiabetic therapy in the elderly patient with type 2 diabetes.
Schlüsselwörter
SGLT-2-Hemmer - GLP-1-Analoga - Alter - Gliflozine - Polypharmazie
Keywords
SGLT-2 inhibitors - GLP-1 analogues - age - gliflozines - polypharmacy
